Verastem, Inc. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
Verastem, Inc. (VSTM) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $558.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-08-06
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $558.00K.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $838.00K.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $278.00K.
- 2020-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $800.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $558.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $838.00K 10-Q · filed 2026-05-07 |
| 2025-09-30 | $278.00K 10-Q · filed 2025-11-04 |
| 2020-06-30 | $800.00K 10-Q · filed 2020-08-10 |
| 2020-03-31 | $1.20M 10-Q · filed 2020-05-07 |
| 2019-09-30 | $400.00K 10-Q · filed 2019-10-30 |
| 2019-06-30 | $800.00K 10-Q · filed 2019-08-01 |
| 2019-03-31 | $1.20M 10-Q · filed 2019-05-09 |
| 2018-09-30 | $392.00K 10-Q · filed 2018-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |